Izokibep, a new IL-17Ai, demonstrated efficacy in treatment of psoriatic arthritis in a phase 2 study with a safety profile similar to other IL-17i. Abs#1597 @RheumNow #ACR22 https://t.co/3LA9u8NsC4

#ACR22 Abstr#0957 Do women with Anti-Ro/La+ get 1st screening for congenital heart block via foetal echo in time (16-18 wks)? A cohort study in 44 pregnancies found only 32% had =<18wks. 5 CHB detected (3 in 1st screening which was >19wks. This needs to improve @RheumNow https://t.co/dqJCCSwGLx

Increasing fracture incidence rates for both AS and comparator groups. Increased in the TNFi era (2004-2021) relative to the pre-TNFi era (2000-2003). The ratio (AS/comparators) appear stable over the past 2 decades Merjanah S Abs1911 https://t.co/lLtW4eh0nm #ACR22 @RheumNow https://t.co/1Nr6ru1vPv

• Trends in Fracture Rates Among Veterans with Ankylosing Spondylitis - ACR Meeti…

Tune in to Twitter, Facebook or LinkedIn daily at 5pm ET. Catch our daily recap LIVE! #ACR22 https://t.co/fgwqIjuXJ4

Lifestyle modifications can affect tx response with TNFi in axSpA! Accdg to this study fr Prof GJones, ✳️Smokers, overwt & obese pts are ⬇️ likely to achieve treatment response to TNFi vs. nonsmokers & normal wt pts Smoking cessation, wt mgt is key! #ACR22 @RheumNow ABST#1510 https://t.co/PBFcj6zKVD

De Craemer et al. Local vs Central reading of images. Rheumatologists overcall sacroiliitis on both plain films and MRI in ?AxSpA . ? some of this out of a desire to try something to help someone who is suffering @RheumNow #ACR22 Abstr#1255 https://t.co/j89E0sUPmN https://t.co/Ez5ldSSQJl

• Rheumatologists Overcall Sacroiliitis on X-ray and MRI in Axial Spondyloarthrit…

Ramahi @sclerodermaUM et al Risk factors for ILD decline in SSc. Anti-Topoisomerase I only identified factor in multivariable model. @RheumNow #ACR22 Abstr#1524 https://t.co/lc2BPjgqiC https://t.co/qx3M6dfd3w

• Risk Factors for Lung Function Decline in Systemic Sclerosis Interstitial Lung …

Plenary: Tyrosine kinase 2 (TYK2) ◦ Mediates signaling of Type I IFNs, IL-23, and IL-12 ◦ Key cytokines involved in lupus pathogenesis ◦ Deucravacitinib oral TYK2 inhibitor ◦ Phase 2 RCT in SLE showed efficacy Pike M Abs1117 https://t.co/eJhNsM02Vl #ACR22 @RheumNow https://t.co/C6JQqR1DLj

• Efficacy and Safety of Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inh…

Doyen et al. FIND-RA study. RA for >1<10 years. RA-ILD 12%, air trapping 58%, rheumatoid nodules 11%. @RheumNow #ACR22 Abstr#1393 https://t.co/Sy1qwZJq5E https://t.co/ww8HgHT32E

• Lung Involvement in Early Rheumatoid Arthritis, Interim Analysis of the FINDRA …

There is an association between the severity of skin and joint or axial disease, both at baseline and longitudinally, in pts presenting w/in 12 months of diagnosis of PsA. Abs 1511 #ACR22 @RheumNow https://t.co/PcVn6dITqU https://t.co/qxn3LBOW8d

• Is There a Correlation Between Skin and Musculoskeletal Activity in Psoriatic A…

Sanchez Martin et al. Assessing effect tocilizumab by PET in GCA. Vascular involvement not generally fully controlled by tocilizumab. Not sure how PET was scored here. @RheumNow #ACR22 Abstr#1257 https://t.co/cGEoScnPb3 https://t.co/W0yYMPMjni

• Assessing the Effectiveness of Tocilizumab in Giant Cell Arteritis by PET: Mult…

Yen et al. Taiwanese study of risk of MACE in SSc. No difference in MACE IRR 1.15 (95%CI 0.87–1.52) or stroke IRR 0.89 (95%CI 0.61-1.29), increase in MI IRR 1.76 (95%CI 1.08-2.86) @RheumNow #ACR22 Abstr#1191 https://t.co/3BiTLafGmk https://t.co/IManEvAh47

• The Risk of Major Adverse Cardiovascular Events in Patients with Systemic Scler…

HZ risk after each (1 of 3) BNT162b2 mRNA vaccination doses was not increased in PsA and AS patients compared to a similar time period two years prior . The risk of HZ increased with age. Abs 1489 #ACR22 @RheumNow https://t.co/YmcqDNoxya

• Incidence of Herpes Zoster Events After the Three Doses of the BNT162b2 mRNA Va…